We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




HOMA2-B Assessed for Type 1 Diabetes Risk

By LabMedica International staff writers
Posted on 26 Jan 2022
Print article
Image: The Homeostasis Model Assessment (HOMA) may have utility as a single-time-point measurement to stratify risk of type 1 diabetes development in autoantibody-positive individuals (Photo courtesy of Adobe Stock)
Image: The Homeostasis Model Assessment (HOMA) may have utility as a single-time-point measurement to stratify risk of type 1 diabetes development in autoantibody-positive individuals (Photo courtesy of Adobe Stock)
Methods to identify individuals at highest risk for type 1 diabetes are essential for the successful implementation of disease-modifying interventions. Simple metabolic measures are needed to help stratify autoantibody-positive (Aab+) individuals who are at risk of developing type 1 diabetes.

The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) and insulin sensitivity (%S), as percentages of a normal reference population. These measures correspond well, but are not necessarily equivalent, to non-steady state estimates of beta cell function and insulin sensitivity derived from stimulatory models such as the hyperinsulinemic clamp, the hyperglycemic clamp, the intravenous glucose tolerance test (acute insulin response, minimal model), and the oral glucose tolerance test.

A team of clinical scientists at the Indiana University School of Medicine (Indianapolis, IN, USA) enrolled in the TrialNet Pathway to Prevention study and measured baseline HOMA2-B values from single- autoantibody-positive (Aab+) 2,652 individuals (mean age, 21.1 ± 14.0 years) and multiple-Aab+ 3, 794 individuals (mean age, 14.5 ± 11.2 years). Cox proportional hazard models were used to determine associations between HOMA2-B tertiles and time to progression to type 1 diabetes, with adjustments for age, sex, HLA status and BMI z score. Receiver operating characteristic (ROC) analysis was used to test the association of HOMA2-B with type 1 diabetes development in 1, 2, 5 and 10 years.

The investigators reported that at study entry, HOMA2-B values were significantly higher in single- compared with multiple-Aab+ participants (91.1 ± 44.5 versus 83.9 ± 38.9). Single- and multiple-Aab+ individuals in the lowest HOMA2-B tertile had a higher risk and faster rate of progression to type 1 diabetes. For progression to type 1 diabetes within 1 year, area under the ROC curve (AUC-ROC) was 0.685, 0.666 and 0.680 for all Aab+, single-Aab+ and multiple-Aab+ individuals, respectively. When correlation between HOMA2-B and type 1 diabetes risk was assessed in combination with additional factors known to influence type 1 diabetes progression (insulin sensitivity, age and HLA status), AUC-ROC was highest for the single-Aab+ group’s risk of progression at 2 years (AUC-ROC 0.723).

The authors concluded that the data suggest that HOMA2-B may have utility as a single-time-point measurement to stratify risk of type 1 diabetes development in Aab+ individuals. The study was published in the January 2022 issue of the journal Diabetologia.

Related Links:
Indiana University School of Medicine

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.